3 Reasons Growth Investors Will Love Amneal (AMRX)

Amneal Pharmaceuticals (AMRX) is highlighted as a growth stock pick by Zacks Investment Research due to its favorable Growth Score of B and Zacks Rank #2 (Buy). The company's EPS is projected to grow 21.8% this year, exceeding the industry average of 16.4%, and its sales are expected to increase by 7.7% versus the industry average of 0%. Additionally, current-year earnings estimates have surged 4.4% over the past month, suggesting a positive outlook for the pharmaceutical company.

Analysis

Amneal Pharmaceuticals (AMRX) presents a compelling case for growth-oriented investors, underscored by its Zacks Rank #2 (Buy) and a Growth Score of B. The company's earnings per share (EPS) are projected to increase by a significant 21.8% this year, substantially outpacing the pharmaceutical industry's average expected EPS growth of 16.4%. This robust earnings outlook is complemented by strong operational efficiency, as evidenced by Amneal's sales-to-total-assets (S/TA) ratio of 0.82. This figure, indicating that the company generates $0.82 in sales for every dollar of assets, is nearly double the industry average of 0.43, suggesting superior asset utilization. Furthermore, Amneal's sales are anticipated to grow by 7.7% this year, a notable figure when contrasted with the flat (0%) sales growth projected for the industry. Reinforcing this positive outlook, current-year earnings estimates for Amneal have seen upward revisions, with the Zacks Consensus Estimate surging by 4.4% over the past month. This combination of strong projected earnings growth, efficient asset management, anticipated sales expansion, and positive earnings estimate revisions positions AMRX favorably within the growth stock category.

Key Decisions for Investors

• Investors seeking growth opportunities may consider Amneal Pharmaceuticals, given its strong projected EPS growth of 21.8% and sales growth of 7.7%, both of which significantly exceed industry averages.
• The combination of a Zacks Rank #2 (Buy) and a Growth Score of B, supported by superior asset utilization and positive earnings estimate revisions, suggests potential for outperformance relative to the market.
• Monitor upcoming earnings reports and any further revisions to analyst estimates, as these will be key indicators of whether the company maintains its current growth trajectory.